English
简体中文
Total: £ 56.28
Published Date: 2024-12-04 | Pages: 110 | Tables: 181 | Medical Care
The global market for Myeloid Cells Targeting Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Myeloid Cells Targeting Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Myeloid Cells Targeting Therapeutics by region & country, by Type, and by Application.
The Myeloid Cells Targeting Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myeloid Cells Targeting Therapeutics.
Market Segmentation
By Company
ChemoCentryx
Daiichi Sankyo
Gilead Sciences
Janssen Biotech
Roche
Pfizer
GlaxoSmithKline
Macrophage Pharma
Enlivex
Immune-Onc Therapeutics
Infinity Pharmaceuticals
AstraZeneca
Segment by Type:
Intravenous Injection
Oral
Segment by Application
Oncological Disorders
Rare Disorders
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Myeloid Cells Targeting Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Myeloid Cells Targeting Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Myeloid Cells Targeting Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Myeloid Cells Targeting Therapeutics Product Introduction
1.2 Global Myeloid Cells Targeting Therapeutics Market Size Forecast
1.3 Myeloid Cells Targeting Therapeutics Market Trends & Drivers
1.3.1 Myeloid Cells Targeting Therapeutics Industry Trends
1.3.2 Myeloid Cells Targeting Therapeutics Market Drivers & Opportunity
1.3.3 Myeloid Cells Targeting Therapeutics Market Challenges
1.3.4 Myeloid Cells Targeting Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Myeloid Cells Targeting Therapeutics Players Revenue Ranking (2023)
2.2 Global Myeloid Cells Targeting Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Myeloid Cells Targeting Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Myeloid Cells Targeting Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Myeloid Cells Targeting Therapeutics
2.6 Myeloid Cells Targeting Therapeutics Market Competitive Analysis
2.6.1 Myeloid Cells Targeting Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Myeloid Cells Targeting Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myeloid Cells Targeting Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Intravenous Injection
3.1.2 Oral
3.2 Global Myeloid Cells Targeting Therapeutics Sales Value by Type
3.2.1 Global Myeloid Cells Targeting Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Myeloid Cells Targeting Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Myeloid Cells Targeting Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncological Disorders
4.1.2 Rare Disorders
4.2 Global Myeloid Cells Targeting Therapeutics Sales Value by Application
4.2.1 Global Myeloid Cells Targeting Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Myeloid Cells Targeting Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Myeloid Cells Targeting Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Myeloid Cells Targeting Therapeutics Sales Value by Region
5.1.1 Global Myeloid Cells Targeting Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Myeloid Cells Targeting Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
5.2.2 North America Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
5.3.2 Europe Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
5.5.2 South America Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value
6.3 United States
6.3.1 United States Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.3.2 United States Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.4.2 Europe Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.5.2 China Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.6.2 Japan Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Myeloid Cells Targeting Therapeutics Sales Value, 2019-2030
6.9.2 India Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Myeloid Cells Targeting Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 ChemoCentryx
7.1.1 ChemoCentryx Profile
7.1.2 ChemoCentryx Main Business
7.1.3 ChemoCentryx Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.1.4 ChemoCentryx Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 ChemoCentryx Recent Developments
7.2 Daiichi Sankyo
7.2.1 Daiichi Sankyo Profile
7.2.2 Daiichi Sankyo Main Business
7.2.3 Daiichi Sankyo Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.2.4 Daiichi Sankyo Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Daiichi Sankyo Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Profile
7.3.2 Gilead Sciences Main Business
7.3.3 Gilead Sciences Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.3.4 Gilead Sciences Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Janssen Biotech Recent Developments
7.4 Janssen Biotech
7.4.1 Janssen Biotech Profile
7.4.2 Janssen Biotech Main Business
7.4.3 Janssen Biotech Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.4.4 Janssen Biotech Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Janssen Biotech Recent Developments
7.5 Roche
7.5.1 Roche Profile
7.5.2 Roche Main Business
7.5.3 Roche Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.5.4 Roche Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Roche Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.6.4 Pfizer Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 GlaxoSmithKline
7.7.1 GlaxoSmithKline Profile
7.7.2 GlaxoSmithKline Main Business
7.7.3 GlaxoSmithKline Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.7.4 GlaxoSmithKline Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 GlaxoSmithKline Recent Developments
7.8 Macrophage Pharma
7.8.1 Macrophage Pharma Profile
7.8.2 Macrophage Pharma Main Business
7.8.3 Macrophage Pharma Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.8.4 Macrophage Pharma Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Macrophage Pharma Recent Developments
7.9 Enlivex
7.9.1 Enlivex Profile
7.9.2 Enlivex Main Business
7.9.3 Enlivex Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.9.4 Enlivex Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 Enlivex Recent Developments
7.10 Immune-Onc Therapeutics
7.10.1 Immune-Onc Therapeutics Profile
7.10.2 Immune-Onc Therapeutics Main Business
7.10.3 Immune-Onc Therapeutics Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.10.4 Immune-Onc Therapeutics Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Immune-Onc Therapeutics Recent Developments
7.11 Infinity Pharmaceuticals
7.11.1 Infinity Pharmaceuticals Profile
7.11.2 Infinity Pharmaceuticals Main Business
7.11.3 Infinity Pharmaceuticals Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.11.4 Infinity Pharmaceuticals Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Infinity Pharmaceuticals Recent Developments
7.12 AstraZeneca
7.12.1 AstraZeneca Profile
7.12.2 AstraZeneca Main Business
7.12.3 AstraZeneca Myeloid Cells Targeting Therapeutics Products, Services and Solutions
7.12.4 AstraZeneca Myeloid Cells Targeting Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 AstraZeneca Recent Developments
8 Industry Chain Analysis
8.1 Myeloid Cells Targeting Therapeutics Industrial Chain
8.2 Myeloid Cells Targeting Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Myeloid Cells Targeting Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Myeloid Cells Targeting Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Myeloid Cells Targeting Therapeutics Market Trends
Table 2. Myeloid Cells Targeting Therapeutics Market Drivers & Opportunity
Table 3. Myeloid Cells Targeting Therapeutics Market Challenges
Table 4. Myeloid Cells Targeting Therapeutics Market Restraints
Table 5. Global Myeloid Cells Targeting Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Myeloid Cells Targeting Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Myeloid Cells Targeting Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Myeloid Cells Targeting Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Myeloid Cells Targeting Therapeutics
Table 10. Global Myeloid Cells Targeting Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myeloid Cells Targeting Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Myeloid Cells Targeting Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Myeloid Cells Targeting Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Myeloid Cells Targeting Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Myeloid Cells Targeting Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Myeloid Cells Targeting Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Myeloid Cells Targeting Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Myeloid Cells Targeting Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Myeloid Cells Targeting Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Myeloid Cells Targeting Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Myeloid Cells Targeting Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Myeloid Cells Targeting Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Myeloid Cells Targeting Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. ChemoCentryx Basic Information List
Table 32. ChemoCentryx Description and Business Overview
Table 33. ChemoCentryx Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of ChemoCentryx (2019-2024)
Table 35. ChemoCentryx Recent Developments
Table 36. Daiichi Sankyo Basic Information List
Table 37. Daiichi Sankyo Description and Business Overview
Table 38. Daiichi Sankyo Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Daiichi Sankyo (2019-2024)
Table 40. Daiichi Sankyo Recent Developments
Table 41. Gilead Sciences Basic Information List
Table 42. Gilead Sciences Description and Business Overview
Table 43. Gilead Sciences Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Gilead Sciences (2019-2024)
Table 45. Gilead Sciences Recent Developments
Table 46. Janssen Biotech Basic Information List
Table 47. Janssen Biotech Description and Business Overview
Table 48. Janssen Biotech Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Janssen Biotech (2019-2024)
Table 50. Janssen Biotech Recent Developments
Table 51. Roche Basic Information List
Table 52. Roche Description and Business Overview
Table 53. Roche Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Roche (2019-2024)
Table 55. Roche Recent Developments
Table 56. Pfizer Basic Information List
Table 57. Pfizer Description and Business Overview
Table 58. Pfizer Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Pfizer (2019-2024)
Table 60. Pfizer Recent Developments
Table 61. GlaxoSmithKline Basic Information List
Table 62. GlaxoSmithKline Description and Business Overview
Table 63. GlaxoSmithKline Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of GlaxoSmithKline (2019-2024)
Table 65. GlaxoSmithKline Recent Developments
Table 66. Macrophage Pharma Basic Information List
Table 67. Macrophage Pharma Description and Business Overview
Table 68. Macrophage Pharma Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Macrophage Pharma (2019-2024)
Table 70. Macrophage Pharma Recent Developments
Table 71. Enlivex Basic Information List
Table 72. Enlivex Description and Business Overview
Table 73. Enlivex Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Enlivex (2019-2024)
Table 75. Enlivex Recent Developments
Table 76. Immune-Onc Therapeutics Basic Information List
Table 77. Immune-Onc Therapeutics Description and Business Overview
Table 78. Immune-Onc Therapeutics Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Immune-Onc Therapeutics (2019-2024)
Table 80. Immune-Onc Therapeutics Recent Developments
Table 81. Infinity Pharmaceuticals Basic Information List
Table 82. Infinity Pharmaceuticals Description and Business Overview
Table 83. Infinity Pharmaceuticals Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of Infinity Pharmaceuticals (2019-2024)
Table 85. Infinity Pharmaceuticals Recent Developments
Table 86. AstraZeneca Basic Information List
Table 87. AstraZeneca Description and Business Overview
Table 88. AstraZeneca Myeloid Cells Targeting Therapeutics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Myeloid Cells Targeting Therapeutics Business of AstraZeneca (2019-2024)
Table 90. AstraZeneca Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Myeloid Cells Targeting Therapeutics Downstream Customers
Table 94. Myeloid Cells Targeting Therapeutics Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Myeloid Cells Targeting Therapeutics Product Picture
Figure 2. Global Myeloid Cells Targeting Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Myeloid Cells Targeting Therapeutics Report Years Considered
Figure 5. Global Myeloid Cells Targeting Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Myeloid Cells Targeting Therapeutics Revenue in 2023
Figure 7. Myeloid Cells Targeting Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Intravenous Injection Picture
Figure 9. Oral Picture
Figure 10. Global Myeloid Cells Targeting Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Myeloid Cells Targeting Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Oncological Disorders
Figure 13. Product Picture of Rare Disorders
Figure 14. Global Myeloid Cells Targeting Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Myeloid Cells Targeting Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 16. North America Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 17. North America Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 18. Europe Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 19. Europe Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 20. Asia Pacific Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 21. Asia Pacific Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 22. South America Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. South America Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 24. Middle East & Africa Myeloid Cells Targeting Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. Middle East & Africa Myeloid Cells Targeting Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 26. Key Countries/Regions Myeloid Cells Targeting Therapeutics Sales Value (%), (2019-2030)
Figure 27. United States Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 28. United States Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 29. United States Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 30. Europe Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 31. Europe Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 32. Europe Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 33. China Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 34. China Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 35. China Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 36. Japan Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 37. Japan Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 38. Japan Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 39. South Korea Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 40. South Korea Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 41. South Korea Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 42. Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 44. Southeast Asia Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 45. India Myeloid Cells Targeting Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 46. India Myeloid Cells Targeting Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 47. India Myeloid Cells Targeting Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 48. Myeloid Cells Targeting Therapeutics Industrial Chain
Figure 49. Myeloid Cells Targeting Therapeutics Manufacturing Cost Structure
Figure 50. Channels of Distribution (Direct Sales, and Distribution)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
